{"id":116198,"date":"2025-09-25T10:26:59","date_gmt":"2025-09-25T01:26:59","guid":{"rendered":"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/"},"modified":"2025-09-25T10:40:47","modified_gmt":"2025-09-25T01:40:47","slug":"downsyndrome-shussezen-kensa","status":"publish","type":"post","link":"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en","title":{"rendered":"Types and Characteristics of Prenatal Tests Related to Down Syndrome"},"content":{"rendered":"\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_84 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">\u76ee\u6b21<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#Introduction\" >Introduction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#1_What_Is_Down_Syndrome\" >1. What Is Down Syndrome<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#2_Classification_of_Prenatal_Tests\" >2. Classification of Prenatal Tests<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#2%E2%80%911_Non%E2%80%91Invasive_Tests_Screening_NIPT_etc\" >2\u20111. Non\u2011Invasive Tests (Screening: NIPT etc.)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#2%E2%80%912_Invasive_Tests_Definitive_Diagnosis\" >2\u20112. Invasive Tests (Definitive Diagnosis)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#3_Key_Points_in_Choosing_a_Test\" >3. Key Points in Choosing a Test<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#4_Recent_Trends_in_NIPT_and_Research_Evidence\" >4. Recent Trends in NIPT and Research Evidence<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#5_Ethical_Considerations_in_Prenatal_Testing\" >5. Ethical Considerations in Prenatal Testing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#6_Examples_of_Clinical_Use\" >6. Examples of Clinical Use<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#7_Summary_So_Far\" >7. Summary So Far<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#8_National_Recommendations_Guidelines_for_Prenatal_Testing\" >8. National Recommendations &amp; Guidelines for Prenatal Testing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#9_Cost_Access_to_Prenatal_Testing\" >9. Cost &amp; Access to Prenatal Testing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#10_Precautions_Before_Undergoing_Prenatal_Testing\" >10. Precautions Before Undergoing Prenatal Testing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#11_Summary_Practical_Tips\" >11. Summary &amp; Practical Tips<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\/#References\" >References<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Introduction\"><\/span>Introduction<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>For many expectant mothers, knowing the fetus\u2019s health status during pregnancy is extremely important. Among congenital chromosomal abnormalities, <strong>Down syndrome (Trisomy 21)<\/strong> is one of the most common. <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/early-nipt-august-only\/\">Early<\/a> risk assessment before birth allows for appropriate medical care and family preparation. In this article, based on the latest research and guidelines, we explain in detail the types and characteristics of prenatal tests related to Down syndrome.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_What_Is_Down_Syndrome\"><\/span>1. What Is Down Syndrome<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Down syndrome is a genetic condition caused by having an extra copy of chromosome 21 (Trisomy 21). Its main features include intellectual disability, characteristic facial features, congenital heart defects, and gastrointestinal anomalies. Prenatal diagnosis enables planning for postnatal medical management, early intervention, and family support.<\/p>\n\n\n\n<p><strong>Incidence<\/strong><br>Globally, the incidence of Down syndrome is approximately 1 in 700 to 1,000 live births (reference: Parker et al., 2010). The risk increases as maternal age rises, especially markedly after 35.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Classification_of_Prenatal_Tests\"><\/span>2. Classification of Prenatal Tests<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Prenatal tests can broadly be classified into <strong>non\u2011invasive<\/strong> tests and <strong>invasive<\/strong> tests. Because their purposes, accuracy, and risks differ, the choice depends on the mother\u2019s condition and preferences.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2%E2%80%911_Non%E2%80%91Invasive_Tests_Screening_NIPT_etc\"><\/span>2\u20111. Non\u2011Invasive Tests (Screening: NIPT etc.)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Non\u2011invasive tests assess the risk of chromosomal abnormalities (such as Down syndrome) by analyzing fetal DNA (cfDNA) in the mother\u2019s blood.<\/p>\n\n\n\n<p>(1) <strong><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> (Non\u2011Invasive Prenatal Testing)<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Characteristics<\/strong>: Assess fetal chromosomal risk by drawing maternal blood. Can be done from around 10 weeks\u2019 gestation onward.<\/li>\n\n\n\n<li><strong>Intended Use<\/strong>: Primarily for high\u2011risk pregnancies (advanced maternal age, ultrasound anomalies, history), but increasingly offered to low\u2011risk pregnancies as well.<\/li>\n\n\n\n<li><strong>Accuracy<\/strong>: Sensitivity for Down syndrome exceeds 99\u202f%, false positive rate about 0.1\u20130.5\u202f% (Bianchi et al., 2014).<\/li>\n\n\n\n<li><strong>Advantages<\/strong>: Non\u2011invasive for mother and fetus; virtually zero miscarriage risk.<\/li>\n\n\n\n<li><strong>Disadvantages<\/strong>: A positive result is not definitive; invasive testing is required for confirmation.<\/li>\n<\/ul>\n\n\n\n<p>(2) <strong>Serum Marker Tests (Maternal Serum Screening)<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Characteristics<\/strong>: Between 15 and 20 weeks gestation, measure specific proteins or hormone levels in maternal serum to estimate Down syndrome risk.<\/li>\n\n\n\n<li><strong>Markers<\/strong>: AFP (alpha\u2011fetoprotein), hCG (human chorionic gonadotropin), uE3 (unconjugated estriol), Inhibin\u2011A, etc.<\/li>\n\n\n\n<li><strong>Accuracy<\/strong>: Sensitivity approximately 70\u201380\u202f%, false positive rate around 5\u202f%. Precision is lower than <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> but cost is lower and usage is more widespread.<\/li>\n\n\n\n<li><strong>Advantages<\/strong>: Relatively simple risk evaluation during pregnancy.<\/li>\n\n\n\n<li><strong>Disadvantages<\/strong>: If result is positive, invasive testing is needed for diagnosis.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2%E2%80%912_Invasive_Tests_Definitive_Diagnosis\"><\/span>2\u20112. Invasive Tests (Definitive Diagnosis)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Invasive tests allow direct fetal chromosomal analysis and can definitively diagnose Down syndrome. However, they carry a small risk of miscarriage for mother and fetus.<\/p>\n\n\n\n<p>(1) <strong>Amniocentesis<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Timing<\/strong>: From around 15 weeks onward<\/li>\n\n\n\n<li><strong>Method<\/strong>: Under ultrasound guidance, amniotic fluid is drawn via the abdomen; fetal cells are cultured and analyzed.<\/li>\n\n\n\n<li><strong>Accuracy<\/strong>: Almost 100\u202f% definitive diagnosis.<\/li>\n\n\n\n<li><strong>Risk<\/strong>: Miscarriage risk approximately 0.1\u20130.3\u202f% (ACOG, 2016).<\/li>\n\n\n\n<li><strong>Advantages<\/strong>: Can detect not only Down syndrome but also other chromosomal anomalies and genetic disorders.<\/li>\n\n\n\n<li><strong>Disadvantages<\/strong>: Invasive, requiring careful decision-making.<\/li>\n<\/ul>\n\n\n\n<p>(2) <strong>Chorionic Villus Sampling (CVS)<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Timing<\/strong>: Between 10 and 13 weeks<\/li>\n\n\n\n<li><strong>Method<\/strong>: Sampling of placental (chorionic villus) tissue for chromosomal analysis.<\/li>\n\n\n\n<li><strong>Accuracy<\/strong>: Provides definitive diagnosis.<\/li>\n\n\n\n<li><strong>Risk<\/strong>: Miscarriage risk roughly 0.5\u202f%, somewhat higher than amniocentesis.<\/li>\n\n\n\n<li><strong>Advantages<\/strong>: Can obtain diagnosis earlier in pregnancy, allowing earlier decision-making.<\/li>\n\n\n\n<li><strong>Disadvantages<\/strong>: It carries miscarriage risk and places burden on mother and fetus.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Key_Points_in_Choosing_a_Test\"><\/span>3. Key Points in Choosing a Test<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>When selecting a prenatal test, the following criteria should be considered:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Type of test<\/li>\n\n\n\n<li>Accuracy<\/li>\n\n\n\n<li>Risk<\/li>\n\n\n\n<li>Timing<\/li>\n\n\n\n<li>Approximate cost<\/li>\n<\/ul>\n\n\n\n<p>Here is a comparative summary:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Test Type<\/th><th>Accuracy<\/th><th>Risk<\/th><th>Timing<\/th><th>Approximate Cost<\/th><\/tr><\/thead><tbody><tr><td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a><\/td><td>High (\u2248 99\u202f%)<\/td><td>Almost none<\/td><td>From 10 weeks onward<\/td><td>~ \u00a5100,000 \u2013 200,000<\/td><\/tr><tr><td>Serum Marker Test<\/td><td>Moderate (70\u201380\u202f%)<\/td><td>None<\/td><td>15\u201320 weeks<\/td><td>Several thousand to ~ \u00a510,000<\/td><\/tr><tr><td>Amniocentesis<\/td><td>Nearly 100\u202f%<\/td><td>Miscarriage risk 0.1\u20130.3\u202f%<\/td><td>From 15 weeks onward<\/td><td>~ \u00a550,000 \u2013 100,000<\/td><\/tr><tr><td>CVS<\/td><td>Nearly 100\u202f%<\/td><td>Miscarriage risk ~0.5\u202f%<\/td><td>10\u201313 weeks<\/td><td>~ \u00a550,000 \u2013 100,000<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>(These figures serve as reference estimates; actual costs and risks differ by region and healthcare institution.)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Recent_Trends_in_NIPT_and_Research_Evidence\"><\/span>4. Recent Trends in NIPT and Research Evidence<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Recent research shows that <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is effective not only in high-risk pregnancies but also in general pregnancies:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bianchi et al., 2014, NEJM<\/strong><br>\u2002In a study of 3,000 high-risk pregnancies, <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> achieved a detection rate of 99.2\u202f% for Down syndrome, with a false positive rate of 0.09\u202f%, demonstrating strong accuracy.<\/li>\n\n\n\n<li><strong>Gil et al., 2015, Obstet Gynecol<\/strong><br>\u2002In 1,200 low-risk pregnancies, <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> outperformed standard serum screening and allowed non\u2011risk prenatal evaluation without miscarriage risk.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Ethical_Considerations_in_Prenatal_Testing\"><\/span>5. Ethical Considerations in Prenatal Testing<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Even though prenatal tests have medical usefulness, they come with ethical implications:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Acceptance of Results<\/strong>: When test results are positive, families must receive thorough genetic counseling and discussion.<\/li>\n\n\n\n<li><strong>Freedom of Choice<\/strong>: Respect the pregnant woman\u2019s autonomy in deciding whether to undertake testing or make prenatal decisions.<\/li>\n\n\n\n<li><strong>Accuracy of Information<\/strong>: Understand that <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is a screening test; a positive result does not equal a definitive diagnosis.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"6_Examples_of_Clinical_Use\"><\/span>6. Examples of Clinical Use<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In practice, prenatal testing is often utilized through the following steps:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Initial risk assessment at prenatal checkups (considering maternal age, ultrasound findings, history)<\/li>\n\n\n\n<li>Perform non\u2011invasive screening (<a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> or serum markers)<\/li>\n\n\n\n<li>If positive or high risk, proceed to invasive testing (amniocentesis or CVS) for definitive diagnosis<\/li>\n\n\n\n<li>With genetic counseling, formulate postnatal medical and support plans<\/li>\n<\/ol>\n\n\n\n<p>This process enables expectant mothers and families to make informed decisions based on clear information.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"7_Summary_So_Far\"><\/span>7. Summary So Far<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Prenatal tests for Down syndrome consist of <strong>non\u2011invasive screenings (<a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a>, serum marker tests)<\/strong> and <strong>invasive tests (amniocentesis, CVS)<\/strong>.<br>While <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> offers high accuracy and safety and is increasingly used by general pregnancies, a positive result is not definitive and must be confirmed invasively.<br>Expectant mothers and families should choose the appropriate test under guidance from medical professionals, considering accuracy, risk, cost, ethics, and psychological aspects.<br>Proper use of prenatal testing makes it easier to plan for postnatal medical management and family support, enabling a safer and more reassuring pregnancy and childbirth experience.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"8_National_Recommendations_Guidelines_for_Prenatal_Testing\"><\/span>8. National Recommendations &amp; Guidelines for Prenatal Testing<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Recommendations for prenatal testing vary by country and medical institution. Because <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is relatively new, its adoption and guidelines differ across regions.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>United States (ACOG)<\/strong><br>\u2002Recommends <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> for advanced\u2011age pregnancies (35+) or those with ultrasound anomalies; also permits offering it to low-risk pregnancies.<\/li>\n\n\n\n<li><strong>United Kingdom (NHS)<\/strong><br>\u2002Performs serum marker screening for all pregnant women initially, and then offers <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> to those at increased risk. <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is treated as a second-tier screening tool.<\/li>\n\n\n\n<li><strong>Japan (Japan Society of Obstetrics and Gynecology)<\/strong><br>\u2002Uses early pregnancy screening (serum markers + NT measurement) for risk assessment; recommends <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> for high-risk pregnancies. If <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is positive, confirm with amniocentesis or other methods.<\/li>\n<\/ul>\n\n\n\n<p>These policies reflect each country\u2019s balance among risk assessment, medical safety, and ethical considerations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"9_Cost_Access_to_Prenatal_Testing\"><\/span>9. Cost &amp; Access to Prenatal Testing<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The cost of prenatal tests differs greatly depending on the method and the healthcare provider.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Test Method<\/th><th>Estimated Cost<\/th><th>Insurance Coverage Possibility<\/th><\/tr><\/thead><tbody><tr><td><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a><\/td><td>~ \u00a5100,000 \u2013 200,000<\/td><td>Usually self\u2011pay (in Japan, often not covered by insurance)<\/td><\/tr><tr><td>Serum Marker Test<\/td><td>Several thousand to ~ \u00a510,000<\/td><td>Usually not covered by health insurance (some local subsidy may apply)<\/td><\/tr><tr><td>Amniocentesis<\/td><td>~ \u00a550,000 \u2013 100,000<\/td><td>If medically indicated, partial insurance coverage may be possible<\/td><\/tr><tr><td>CVS<\/td><td>~ \u00a550,000 \u2013 100,000<\/td><td>Mostly self-pay (insurance support possible if medically justified)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Expectant mothers and families should include financial considerations in their decision-making. Although <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is expensive, its low risk and high accuracy give it considerable value.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"10_Precautions_Before_Undergoing_Prenatal_Testing\"><\/span>10. Precautions Before Undergoing Prenatal Testing<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Before undergoing prenatal testing, the mother and her family should understand the following:<\/p>\n\n\n\n<p><strong>Medical ethics &amp; legal constraints<\/strong><br>\u2002The purposes of testing and regulations concerning termination of pregnancy vary by country; thorough information gathering is essential.<\/p>\n\n\n\n<p><strong>Difference between screening and diagnosis<\/strong><br>\u2002Despite high accuracy, <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is a screening test. A positive result necessitates invasive testing for confirmation.<\/p>\n\n\n\n<p><strong>Possibility of false negatives \/ false positives<\/strong><br>\u2002Not all chromosomal abnormalities can be detected; rare misclassifications may occur.<\/p>\n\n\n\n<p><strong>Psychological impact<\/strong><br>\u2002Results can impose emotional stress. Professional genetic counseling and psychological support are vital.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img decoding=\"async\" width=\"640\" height=\"427\" src=\"\/nipt\/wp-content\/uploads\/2025\/09\/24914789_s.webp\" alt=\"\u533b\u8005\" class=\"wp-image-116189\"\/><\/figure><\/div>\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"11_Summary_Practical_Tips\"><\/span>11. Summary &amp; Practical Tips<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Risk evaluation for Down syndrome in pregnancy is divided into <strong>non\u2011invasive tests (<a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a>, serum markers)<\/strong> and <strong>invasive tests (amniocentesis, CVS)<\/strong>.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> offers high accuracy and safety, relieving psychological burden on expectant mothers, but it is not diagnostic.<\/li>\n\n\n\n<li>Amniocentesis and CVS can provide definitive diagnosis but carry a small risk of miscarriage.<\/li>\n\n\n\n<li>When choosing tests, one must weigh accuracy, risk, cost, ethics, and psychological factors together.<\/li>\n\n\n\n<li>Pre\u2011 and post-test counseling enables mothers and families to make well-informed decisions.<\/li>\n\n\n\n<li>With advances in prenatal testing technology, expectant mothers and families may increasingly have safer, more accurate testing options. Working collaboratively with medical professionals, choosing the appropriate tests, and obtaining support are crucial.<\/li>\n<\/ul>\n\n\n\n<p>By properly using prenatal testing, expectant mothers and families can better plan medical care and support post-birth, making pregnancy and childbirth a more reassuring experience.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"References\"><\/span><strong>References<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Parker SE, Mai CT, Canfield MA, et al. Updated National Birth Prevalence Estimates for Selected Birth Defects in the United States, 2004\u20132006. Birth Defects Res A Clin Mol Teratol. 2010;88(12):1008\u20131016.<br>Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;370:799\u2013808.<br>Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell\u2011free DNA in maternal blood in screening for aneuploidies: updated meta\u2011analysis. Obstet Gynecol. 2015;126(3):514\u2013524.<br>ACOG Practice Bulletin No. 163. Screening for Fetal Aneuploidy. Obstet Gynecol. 2016;127:e123\u2013e137.<br>Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive Prenatal Testing for Fetal Aneuploidy: Current Status and Future Prospects. Prenatal Diagnosis. 2015;35(6):621\u2013626.<br>NHS Fetal Anomaly Screening Programme. Policy and Guidelines. 2023.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"Introduction For man&#8230;\n <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/downsyndrome-shussezen-kensa\/?lang=en\">\u7d9a\u304d\u3092\u8aad\u3080<\/a>","protected":false},"author":122,"featured_media":116188,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[97],"tags":[],"class_list":["post-116198","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/116198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/users\/122"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/comments?post=116198"}],"version-history":[{"count":2,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/116198\/revisions"}],"predecessor-version":[{"id":116212,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/116198\/revisions\/116212"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/media\/116188"}],"wp:attachment":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/media?parent=116198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/categories?post=116198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/tags?post=116198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}